Vericel Corporation (VCEL)

Market Cap	2.35B
Revenue (ttm)	207.78M
Net Income (ttm)	451,000
Shares Out	48.60M
EPS (ttm)	0.01
PE Ratio	4,835.00
Forward PE	499.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,594
Open	47.79
Previous Close	47.61
Day's Range	47.09 - 48.54
52-Week Range	30.18 - 53.05
Beta	1.75
Analysts	Strong Buy
Price Target	46.00 (-4.86%)
Earnings Date	May 8, 2024

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 1997
• Employees: 314
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL

Financial Performance

In 2023, Vericel's revenue was $197.52 million, an increase of 20.17% compared to the previous year's $164.37 million. Losses were -$3.18 million, -80.96% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price forecast is $46.0, which is a decrease of -4.86% from the latest price.

Price Target

$46.0

(-4.86% downside)

Analyst Consensus: Strong Buy